Additionally, the inhibition of VEGFR-3 with receptor-specific antagonist antibodies was shown to suppress tumor lymphangiogenesis as well as regional and distant metastasis (Roberts et al., 2006). This evidence concerns the gene FLT4 and neoplasm.